CN113056263A - 治疗化合物和组合物 - Google Patents

治疗化合物和组合物 Download PDF

Info

Publication number
CN113056263A
CN113056263A CN201980072155.7A CN201980072155A CN113056263A CN 113056263 A CN113056263 A CN 113056263A CN 201980072155 A CN201980072155 A CN 201980072155A CN 113056263 A CN113056263 A CN 113056263A
Authority
CN
China
Prior art keywords
subject
compound
pharmaceutically acceptable
acceptable salt
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980072155.7A
Other languages
English (en)
Chinese (zh)
Inventor
N.J.海沃德
B.L.切纳德
Y.徐
R.L.多罗
M.E.马丁森
A.科尔钦斯基
R.福尼科拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exithera Pharmaceuticals Inc
Original Assignee
Exithera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exithera Pharmaceuticals Inc filed Critical Exithera Pharmaceuticals Inc
Publication of CN113056263A publication Critical patent/CN113056263A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/04—Use of organic materials, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
CN201980072155.7A 2018-10-30 2019-10-30 治疗化合物和组合物 Pending CN113056263A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752510P 2018-10-30 2018-10-30
US62/752,510 2018-10-30
PCT/US2019/058898 WO2020092594A1 (en) 2018-10-30 2019-10-30 Therapeutic compounds and compositions

Publications (1)

Publication Number Publication Date
CN113056263A true CN113056263A (zh) 2021-06-29

Family

ID=70464743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980072155.7A Pending CN113056263A (zh) 2018-10-30 2019-10-30 治疗化合物和组合物

Country Status (10)

Country Link
US (1) US20210253550A1 (https=)
EP (1) EP3873446A4 (https=)
JP (1) JP2022506109A (https=)
KR (1) KR20210084581A (https=)
CN (1) CN113056263A (https=)
AU (1) AU2019369518A1 (https=)
BR (1) BR112021008462A2 (https=)
CA (1) CA3117549A1 (https=)
IL (1) IL282765A (https=)
WO (1) WO2020092594A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023185852A1 (zh) * 2022-03-30 2023-10-05 四川海思科制药有限公司 一种环状内酰胺类化合物的注射用药物组合物及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
EP3749662A4 (en) 2018-02-07 2021-07-14 Exithera Pharmaceuticals Inc. THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
CA2648522A1 (en) * 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
KR101937514B1 (ko) * 2011-10-14 2019-01-10 브리스톨-마이어스 스큅 컴퍼니 인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물
RU2733405C2 (ru) * 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
US20190315711A1 (en) * 2016-12-23 2019-10-17 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2020092592A1 (en) * 2018-10-30 2020-05-07 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP3917910A4 (en) * 2019-01-29 2022-11-09 Exithera Pharmaceuticals Inc. THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023185852A1 (zh) * 2022-03-30 2023-10-05 四川海思科制药有限公司 一种环状内酰胺类化合物的注射用药物组合物及其制备方法

Also Published As

Publication number Publication date
BR112021008462A2 (pt) 2021-08-03
EP3873446A1 (en) 2021-09-08
CA3117549A1 (en) 2020-05-07
US20210253550A1 (en) 2021-08-19
IL282765A (en) 2021-06-30
KR20210084581A (ko) 2021-07-07
WO2020092594A1 (en) 2020-05-07
JP2022506109A (ja) 2022-01-17
EP3873446A4 (en) 2022-08-03
AU2019369518A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
JP6154473B2 (ja) 第ＸＩａ因子阻害剤の結晶形
US20210261524A1 (en) Therapeutic compounds and compositions
RU2707887C2 (ru) Производное дигидроиндолизинона
JP2017507933A (ja) 治療用化合物および組成物
US20230270731A1 (en) Therapeutic compounds and compositions
US20210253550A1 (en) Therapeutic compounds and compositions
WO2018118705A1 (en) Therapeutic compounds and compositions
JP2024023490A (ja) 治療用化合物および組成物
TWI826599B (zh) （３ｓ）－３－［２－（６－胺－２－氟吡啶－３－基）－４－氟－１ｈ－咪唑－５－基］－７－［５－氯－２－（１ｈ－四唑－１－基）苯基］－２，３－二氫吲嗪－５（１ｈ）－酮的新穎結晶
JP2023521411A (ja) （９ｒ，１３ｓ）－１３－｛４－［５－クロロ－２－（４－クロロ－１ｈ－１，２，３－トリアゾール－１－イル）フェニル］－６－オキソ－１，６－ジヒドロピリミジン－１－イル｝－３－（ジフルオロメチル）－９－メチル－３，４，７，１５－テトラアザトリシクロ［１２．３．１．０２，６］オクタデカ－１（１８），２（６），４，１４，１６－ペンタエン－８－オンの結晶体
RU2813780C2 (ru) Терапевтические соединения и композиции
CN116782911A (zh) 治疗性化合物、组合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210629